# Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab

> **NCT04928573** · — · COMPLETED · sponsor: **Libbs Farmacêutica LTDA** · enrollment: 27 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04928573
- **Lead sponsor:** Libbs Farmacêutica LTDA
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-08
- **Primary completion:** 2022-07-29
- **Final completion:** 2023-03-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04928573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04928573, "Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04928573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*